| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
7-Ketocholesterol is a bioactive molecule involved in various pathological conditions, particularly in cardiovascular diseases and neurodegenerative disorders like Alzheimer's. It contributes to endothelial dysfunction, promotes inflammation, and can damage cellular membranes, accelerating atherosclerosis and plaque formation. It is a metabolite of Cholesterol and is formed through the nonenzymatic oxidation of cholesterol.
|
|---|---|
| ln Vitro |
In vitro, 7-Ketocholesterol is a bioactive oxysterol that contributes to endothelial dysfunction, promotes inflammation, and damages cellular membranes. It is used in research to study the effects of oxidized LDL and the pathogenesis of atherosclerosis and neurodegenerative diseases.
|
| ln Vivo |
In vivo, 7-Ketocholesterol is involved in various pathological conditions, particularly in cardiovascular diseases and neurodegenerative disorders. It accelerates atherosclerosis and plaque formation and contributes to endothelial dysfunction and inflammation.
|
| Enzyme Assay |
In vitro assays for 7-Ketocholesterol involve studying its effects on cells, such as endothelial cells or neuronal cells, to assess its role in inflammation, oxidative stress, and cell damage. Cells are treated with various concentrations of the compound, and markers of inflammation, oxidative stress, and cell viability are measured.
|
| Cell Assay |
In vitro cellular assays for 7-Ketocholesterol are performed using endothelial cells, macrophages, or neuronal cells to study its effects on inflammation, oxidative stress, and cell damage. Cells are treated with the compound, and cytokine production, reactive oxygen species (ROS) levels, and cell viability are assessed.
|
| Animal Protocol |
In vivo animal studies with 7-Ketocholesterol are conducted in models of atherosclerosis or neurodegenerative diseases to study its role in disease pathogenesis. The compound is administered, and its effects on plaque formation, inflammation, and neuronal damage are assessed.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of 7-Ketocholesterol are not extensively reported. As an oxysterol, it is a metabolite of cholesterol and is formed through nonenzymatic oxidation. Specific parameters such as bioavailability and half-life are not detailed.
|
| Toxicity/Toxicokinetics |
The toxicity profile of 7-Ketocholesterol is related to its pathological effects. It contributes to endothelial dysfunction, promotes inflammation, and can damage cellular membranes. At high concentrations, it is toxic to cells and is involved in the pathogenesis of atherosclerosis and neurodegenerative diseases.
|
| References | |
| Additional Infomation |
7-Ketocholesterol is a cholesterol alkyl group consisting of cholesterol with an oxygen substituent at the 7-position. It has neuroprotective effects. It is a 3β-sterol, cholesterol alkyl group, 7-oxosteroid, and 3β-hydroxy-Δ5-steroid. Its function is related to cholesterol. 7-Ketocholesterol has been reported to exist in Cliona copiosa, Costus tonkinensis, and several other organisms with relevant data.
7-Ketocholesterol (CAS 566-28-9) is a cholesterol oxidation product and a major oxysterol component of oxidized LDL. It has a molecular formula of C27H44O2. The compound is involved in cardiovascular diseases and neurodegenerative disorders and is used in research to study these pathologies. It is available for research purposes only. |
| Molecular Formula |
C27H44O2
|
|---|---|
| Molecular Weight |
400.63706
|
| Exact Mass |
400.334
|
| CAS # |
566-28-9
|
| Related CAS # |
7-Keto Cholesterol-d7;127684-08-6
|
| PubChem CID |
91474
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
516.7±29.0 °C at 760 mmHg
|
| Melting Point |
158-160ºC
|
| Flash Point |
218.5±16.9 °C
|
| Vapour Pressure |
0.0±3.0 mmHg at 25°C
|
| Index of Refraction |
1.531
|
| Source |
Endogenously produced metabolite: human
|
| LogP |
7.57
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
29
|
| Complexity |
663
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C(=O)C=C4[C@@]3(CC[C@@H](C4)O)C)C
|
| InChi Key |
YIKKMWSQVKJCOP-ABXCMAEBSA-N
|
| InChi Code |
InChI=1S/C27H44O2/c1-17(2)7-6-8-18(3)21-9-10-22-25-23(12-14-27(21,22)5)26(4)13-11-20(28)15-19(26)16-24(25)29/h16-18,20-23,25,28H,6-15H2,1-5H3/t18-,20+,21-,22+,23+,25+,26+,27-/m1/s1
|
| Chemical Name |
(3S,8S,9S,10R,13R,14S,17R)-3-hydroxy-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-1,2,3,4,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-7-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 12.5 mg/mL (~31.20 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.62 mg/mL (1.55 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (6.2 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.61 mg/mL (1.52 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (6.1 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 0.61 mg/mL (1.52 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (6.1 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4960 mL | 12.4800 mL | 24.9601 mL | |
| 5 mM | 0.4992 mL | 2.4960 mL | 4.9920 mL | |
| 10 mM | 0.2496 mL | 1.2480 mL | 2.4960 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
